Pfizer begins safety testing of experimental kidney drug in healthy people
NCT ID NCT07235150
First seen Nov 19, 2025 · Last updated May 24, 2026 · Updated 21 times
Summary
This early-stage study tests a new medicine called PF-07985631, which may one day treat a kidney disease called IgA nephropathy. About 76 healthy adults aged 18 to 55 will receive either the drug or a placebo as a small injection. The main goal is to check safety and how the body processes the drug, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Q-Pharm Pty Ltd. (Nucleus Network)
RECRUITINGHerston, Queensland, 4006, Australia
Conditions
Explore the condition pages connected to this study.